PMUC1CALLO-1 is under clinical development by Poseida Therapeutics and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I drugs for Pancreatic Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PMUC1CALLO-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
P-MUC1CALLO-1 is under development for the treatment of solid tumors derived from epithelial cells tumors including triple-negative breast cancer, renal cancer, ovarian cancer, non-small cell lung cancer, esophageal cancer, gastric cancer, pancreatic cancer and colorectal cancers. It comprises of allogeneic stem memory T cells (Tscm), genetically engineered to express chimeric antigen receptor (CAR). It acts by targeting the cells expressing mucin1. The therapeutic candidate is being developed based on Piggybac DNA modification system and CAS Clover gene-editing technology.
Poseida Therapeutics overview
Poseida Therapeutics is a biopharmaceutical company. It harnesses its proprietary gene engineering platform, to develop next generation cell and gene therapeutics to treat solid tumors and hematological malignancies. The company is investigating its lead product candidate P-BCMA-101, an autologous CAR-T therapy against refractory multiple myeloma. It is also evaluating P-PSMA-101 and P-PSMA-ALL01, allogeneic chimeric antigen receptors for the treatment of prostate cancer; and Dual car (CD19/CD20) targeting solid tumor. Poseida Therapeutics is headquartered in San Diego, California, the US.
For a complete picture of PMUC1CALLO-1’s drug-specific PTSR and LoA scores, buy the report here.